1. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47:1952
2. Clark PI, Joel SP, Slevin ML (1989) A pharmacokinetic hypothesis for the clinical efficacy of etoposide in small cell lung cancer. Proc Am Soc Clin Oncol 8:66
3. Dombernowsky P, Nissen NI (1973) Schedule dependency of the antileukemic activity of the podophyllotoxin derivative VP-16-213 (NSC141540) in L1210 leukemia. Arch Pathol Microbiol Scand 81:715
4. Drewinko B, Barlogie B (1976) Survival and cycle progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat Rep 60:1295
5. Fleming RA, Miller AA, Stewart CF (1989) Etoposide: an update. Clin Pharm 8:274